68 related articles for article (PubMed ID: 16203798)
1. PIK3CA mutations in ovarian cancer.
Campbell IG; Russell SE; Phillips WA
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7042; author reply 7042-3. PubMed ID: 16203798
[No Abstract] [Full Text] [Related]
2. Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.
Huang HN; Chiang YC; Cheng WF; Chen CA; Lin MC; Kuo KT
Mod Pathol; 2015 Feb; 28(2):303-11. PubMed ID: 25081752
[TBL] [Abstract][Full Text] [Related]
3. PIK3CA in ovarian clear cell carcinoma.
Zannoni GF; Improta G; Fraggetta F
Hum Pathol; 2014 Dec; 45(12):2514. PubMed ID: 25245602
[No Abstract] [Full Text] [Related]
4. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma.
Yamamoto S; Tsuda H; Takano M; Iwaya K; Tamai S; Matsubara O
J Pathol; 2011 Oct; 225(2):189-94. PubMed ID: 21735444
[TBL] [Abstract][Full Text] [Related]
6. PIK3CA gene mutations and amplifications in Chinese patients with ovarian clear cell carcinoma.
Jiang G; Huang Z; Zhang S; Wang L
Cancer Invest; 2013 Dec; 31(10):639-44. PubMed ID: 24299208
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
[TBL] [Abstract][Full Text] [Related]
8. PI3KCA in ovarian clear cell carcinoma-reply.
Nakayama K; Kyo S
Hum Pathol; 2014 Dec; 45(12):2515. PubMed ID: 25257578
[No Abstract] [Full Text] [Related]
9. Alternate molecular genetic pathways in ovarian carcinomas of common histological types.
Willner J; Wurz K; Allison KH; Galic V; Garcia RL; Goff BA; Swisher EM
Hum Pathol; 2007 Apr; 38(4):607-13. PubMed ID: 17258789
[TBL] [Abstract][Full Text] [Related]
10. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.
McConechy MK; Anglesio MS; Kalloger SE; Yang W; Senz J; Chow C; Heravi-Moussavi A; Morin GB; Mes-Masson AM; ; Carey MS; McAlpine JN; Kwon JS; Prentice LM; Boyd N; Shah SP; Gilks CB; Huntsman DG
J Pathol; 2011 Apr; 223(5):567-73. PubMed ID: 21381030
[TBL] [Abstract][Full Text] [Related]
11. PIK3CA mutations in advanced ovarian carcinomas.
Wang Y; Helland A; Holm R; Kristensen GB; Børresen-Dale AL
Hum Mutat; 2005 Mar; 25(3):322. PubMed ID: 15712344
[TBL] [Abstract][Full Text] [Related]
12. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
[TBL] [Abstract][Full Text] [Related]
13. Ovarian clear cell carcinoma--bad endometriosis or bad endometrium?
Gounaris I; Charnock-Jones DS; Brenton JD
J Pathol; 2011 Oct; 225(2):157-60. PubMed ID: 21898874
[TBL] [Abstract][Full Text] [Related]
14. PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma.
Abe A; Minaguchi T; Ochi H; Onuki M; Okada S; Matsumoto K; Satoh T; Oki A; Yoshikawa H
Hum Pathol; 2013 Feb; 44(2):199-207. PubMed ID: 22955107
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
[TBL] [Abstract][Full Text] [Related]
16. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.
Velasco A; Bussaglia E; Pallares J; Dolcet X; Llobet D; Encinas M; Llecha N; Palacios J; Prat J; Matias-Guiu X
Hum Pathol; 2006 Nov; 37(11):1465-72. PubMed ID: 16949921
[TBL] [Abstract][Full Text] [Related]
17. Rare mutations in the PIK3CA gene contribute to aggressive endometrial cancer.
Konstantinova D; Kaneva R; Dimitrov R; Savov A; Ivanov S; Dyankova T; Kremensky I; Mitev V
DNA Cell Biol; 2010 Feb; 29(2):65-70. PubMed ID: 19839777
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
Konopka B; Janiec-Jankowska A; Kwiatkowska E; Najmoła U; Bidziński M; Olszewski W; Goluda C
Hum Pathol; 2011 Nov; 42(11):1710-9. PubMed ID: 21531001
[TBL] [Abstract][Full Text] [Related]
19. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
[TBL] [Abstract][Full Text] [Related]
20. Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1.
Rudd ML; Mohamed H; Price JC; O'Hara AJ; Le Gallo M; Urick ME; ; Cruz P; Zhang S; Hansen NF; Godwin AK; Sgroi DC; Wolfsberg TG; Mullikin JC; Merino MJ; Bell DW
BMC Cancer; 2014 Nov; 14():884. PubMed ID: 25427824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
